信立泰(002294.SZ)：SAL0145药品临床试验申请获得受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its innovative drug SAL0145 injection, which targets Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) [1] Group 1: Product Development - SAL0145 is an innovative drug developed by the company, aimed at treating MASH, a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [1] - MASH affects approximately 30% of the adult population globally, and if left untreated, it can progress to cirrhosis or liver cancer, posing significant health risks to patients [1] - Preclinical studies indicate that SAL0145 has the potential to treat MASH, and successful development and approval could provide new treatment options for patients, addressing unmet clinical needs [1] Group 2: Market Implications - The approval of SAL0145 would enrich the company's pipeline of innovative products in the chronic disease sector, potentially enhancing its market position [1]